At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
02186 LUYE PHARMA
Not Yet Opened 12-11 16:08:03
2.880
-0.080
-2.70%
High2.970Low2.860Vol23.91M
Open2.960D1 Closing2.960Amplitude3.72%
Mkt Cap11.51BTradable Cap11.51BTotal Shares4.00B
T/O69.34MT/O Rate0.60%Tradable Shares4.00B
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
Luye Pharma Says Five New Products Added to China's Drug Reimbursement List
MT Newswires Live  ·  12-08
Luye Pharma Says Five New Products Added to China's Drug Reimbursement List
HK Stock Movement | LUYE PHARMA (02186) Rises Nearly 3% as Five New Products Including Mimexin® Included in National Reimbursement Drug List or Commercial Insurance Innovative Drug Directory
Stock News  ·  12-08
HK Stock Movement | LUYE PHARMA (02186) Rises Nearly 3% as Five New Products Including Mimexin® Included in National Reimbursement Drug List or Commercial Insurance Innovative Drug Directory
LUYE PHARMA (02186) Successfully Includes Five New Products in 2025 National Reimbursement Drug List or Commercial Insurance Innovative Drug Directory
Stock News  ·  12-07
LUYE PHARMA (02186) Successfully Includes Five New Products in 2025 National Reimbursement Drug List or Commercial Insurance Innovative Drug Directory
Southbound Capital Flow Data (T+2) for Hong Kong Stocks | November 27
Stock News  ·  11-27
Southbound Capital Flow Data (T+2) for Hong Kong Stocks | November 27
HK Stock Movement | LUYE PHARMA (02186) Rises Over 3% as New Drug LY03017 Approved for Clinical Trials in the U.S. Targeting PDP and Other Conditions
Stock News  ·  11-26
HK Stock Movement | LUYE PHARMA (02186) Rises Over 3% as New Drug LY03017 Approved for Clinical Trials in the U.S. Targeting PDP and Other Conditions
Luye Pharma Wins FDA IND Clearance for Next-Generation CNS Drug LY03017
Reuters  ·  11-24
Luye Pharma Wins FDA IND Clearance for Next-Generation CNS Drug LY03017
Luye Pharma Gets U.S. FDA Nod to Start Trials for New CNS Drug
MT Newswires Live  ·  11-24
Luye Pharma Gets U.S. FDA Nod to Start Trials for New CNS Drug
BRIEF-Luye Pharma Says Approval Obtained For LY03017 For Clinical Trials In U.S.
Reuters  ·  11-24
BRIEF-Luye Pharma Says Approval Obtained For LY03017 For Clinical Trials In U.S.
LUYE PHARMA (02186) Receives FDA Approval for Clinical Trials of New Drug LY03017 in the U.S.
Stock News  ·  11-24
LUYE PHARMA (02186) Receives FDA Approval for Clinical Trials of New Drug LY03017 in the U.S.
Luye Pharma (02186) Gains U.S. FDA Clearance for CNS Drug LY03017
Bulletin Express  ·  11-24
Luye Pharma (02186) Gains U.S. FDA Clearance for CNS Drug LY03017
Luye Pharma - Approval Obtained for Group's New Drug Ly03017 for Clinical Trials in U.S.
THOMSON REUTERS  ·  11-24
Luye Pharma - Approval Obtained for Group's New Drug Ly03017 for Clinical Trials in U.S.
Luye Pharma Unit to Raise $150 Million via Boan-Linked Exchangeable Shares
MT Newswires Live  ·  11-21
Luye Pharma Unit to Raise $150 Million via Boan-Linked Exchangeable Shares
Luye Pharma Group (02186) Announces US$150 Million Exchangeable Preference Shares Linked to Boan Biotech (06955)
Bulletin Express  ·  11-21
Luye Pharma Group (02186) Announces US$150 Million Exchangeable Preference Shares Linked to Boan Biotech (06955)
Luye Pharma Subsidiary Issues Exchangeable Preference Shares
Reuters  ·  11-21
Luye Pharma Subsidiary Issues Exchangeable Preference Shares
Market Participants Recognise Luye Pharma Group Ltd.'s (HKG:2186) Earnings
Simply Wall St.  ·  11-11
Market Participants Recognise Luye Pharma Group Ltd.'s (HKG:2186) Earnings
HK Stock Connect Shareholding Changes | Oct 28
Stock News  ·  10-28
HK Stock Connect Shareholding Changes | Oct 28
Does the Recent 7.7% Price Jump Signal a New Outlook for Luye Pharma Group in 2025?
Simply Wall St.  ·  10-07
Does the Recent 7.7% Price Jump Signal a New Outlook for Luye Pharma Group in 2025?
Is Luye Pharma Group (SEHK:2186) Overvalued? A Fresh Look at Its Current Share Price and P/E Ratio
Simply Wall St.  ·  10-03
Is Luye Pharma Group (SEHK:2186) Overvalued? A Fresh Look at Its Current Share Price and P/E Ratio
Shandong Boan Biotechnology Reports 8.4% Rise in Revenue to RMB393.4 Million and Net Profit of RMB20.5 Million for H1 2025
Reuters  ·  09-29
Shandong Boan Biotechnology Reports 8.4% Rise in Revenue to RMB393.4 Million and Net Profit of RMB20.5 Million for H1 2025
Huaan Securities Maintains "Buy" Rating on LUYE PHARMA, Optimistic About Global Sales Platform Capabilities
Stock News  ·  09-29
Huaan Securities Maintains "Buy" Rating on LUYE PHARMA, Optimistic About Global Sales Platform Capabilities

Introduction

Company Name.
LUYE PHARMA
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
Luye Pharma Group Ltd is a company mainly engaged in developing, producing, marketing and selling pharmaceutical products. The Company operates four segments, including Oncology Drugs segment, Cardiovascular System Drugs segment, Alimentary Tract and Metabolism Drugs segment, and Central Nervous System Drugs segment. The Oncology Drugs segment provides Lipusu, Boyounuo, Baituowei, CMNa and Mimeixin and other drugs. The Cardiovascular System Drugs segment provides Xuezhikang, Oukai and Maitongna and other drugs. The Alimentary Tract and Metabolism Drugs segment provides Bei Xi and other drugs. The Central Nervous System Drugs segment provides Seroquel, Ruoxinlin, Rykindo, Meibirui and Jinyouping and other drugs.
Issue price:
--